Coronary Heart Disease
Conditions
Keywords
Glycocalyx, Inflammation, Oxidative stress, Endothelium, Coronary Artery Disease, Myocardial Revascularization
Brief summary
The primary research objective of the project is to determine the role of eGC in microvascular reactivity in patients with coronary heart disease (CHD) before and after bypass grafting (cross-sectional study 2).The main objective of the project is to increase the excellence and interdisciplinarity of scientific work at MEFOS by connecting researchers from different scientific fields, improving conditions and resources for scientific work, and increasing international cooperation, in line with strategic objective 1: raising scientific excellence. The results of the project could provide pathophysiological insight into the development and maintenance of endothelial dysfunction in CVD, as well as identify new biomarkers for CVD.
Detailed description
The primary objective of this project is to determine the association between endothelial glycocalyx (eGC) and myocardial revascularization in patients undergoing coronary artery bypass grafting and clinical outcomes of treatment (observational prospective study 2). Specific objective 2.1: Measure eGC thickness in coronary artery disease patients before and after surgery. Specific objective 2.2: Determine the reactivity of the bypass graft sample in in vitro experiments. Specific objective 2.3: Quantify soluble markers of eGC, oxidative stress, and inflammation from serum and PBMC samples, as well as antioxidant capacity. Specific objective 2.4: Determine the association between the results of functional tests, eGC, and markers from specific objective 2.3 with clinical outcomes of treatment.
Interventions
None listed
Sponsors
Josip Juraj Strossmayer University of Osijek
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult patients of both sexes over 18 years of age * Caucasian * undergoing elective coronary artery bypass grafting (CABG) * provided written informed consent
Exclusion criteria
* emergency surgery * sepsis or severe systemic inflammation before surgery * severe renal or hepatic insufficiency * immunosuppression * serious comorbidities (e.g., active cancer) * therapies that could affect oxidative stress (e.g., high doses of corticosteroids)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endothelial glycocalyx | Perioperative/Periprocedural | Measurement of the thickness of endothelial glycocalyx in coronary heart disease patients before and after bypass surgery - measured by Glycocheck |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bypass graft sample reactivity | Baseline, at one time point | Determine the reactivity of the bypass graft sample in in vitro experiments - measured by isolated vessel setup |
| Endothelial glycocalyx soluble markers | Perioperative/Periprocedural | Quantification of soluble markers of endothelial glycocalyx from serum or plasma samples in the specified groups - measured by ELISA assays (syndecan-1, syndecan-4, glypican-1, MMP-9) |
| Intracellular oxidative stress production | Perioperative/Periprocedural | Quantification of intracellular oxidative stress production from peripheral blood mononuclear cells (PBMC) in the specified groups - measured by flow cytometry (DCF-DA and DHE) |
| Inflammation | Perioperative/Periprocedural | Quantification of inflammation from peripheral blood mononuclear cells (PBMC) in the specified groups - measured by Luminex assay (cytokine profile) and flow cytometry (macrophage frequency) |
| Antioxidant capacity | Perioperative/Periprocedural | Quantification of antioxidative enzyme concentration and activation from serum samples in the specified groups - measured by ELISA assays and UV-Vis spectrophotometry (SOD, GPx, CAT) |
| Oxidative stress biomarkers | Perioperative/Periprocedural | Quantification of oxidative stress biomarkers from serum samples in the specified groups - measured by ELISA assays (MPO, 8-iso prostaglandin F2a, OxLDL, AOPP) |
Countries
Croatia
Contacts
CONTACTInes Drenjančević, MD, PhD
Outcome results
None listed